Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

China Beefs Up Quality Control System With New GMP Regulations: Shanghai FDA Leaders At PharmAsia Summit

This article was originally published in PharmAsia News

Executive Summary

SAN FRANCISCO - China is releasing a new edition of its good manufacturing practice regulations and introducing other measures to strength its pharmaceutical quality control system. China's State FDA is placing more focus on reviewing drugs for approval while provincial-level regulators have stepped-up responsibility for inspecting drug makers and monitoring drugs on the market, said Shanghai FDA officers who spoke at the PharmAsia Summit this week in San Francisco

You may also be interested in...



Insider Analysis From Asia Pacific Bio Intelligence LLC On China State FDA’s Medical Device Regulations

For China’s State FDA, 2011 was a banner year, with regulations released on good manufacturing practices for both drugs and devices. Multinational companies should take notice and be sure their operations are in compliance.

China One Step Closer To Global Standards For Drug Quality With Rollout Of New GMP Guidelines

SHANGHAI - China's State FDA recently issued a note to provincial FDA offices to require pharma companies and active pharmaceutical ingredient producers to file a Common Technical Document when they submit manufacturing applications as an effort to improve drug quality and research and development work in China

China Implements New Quality System To Strengthen Drug Safety; Puts Legal Onus On Drug Quality Attorneys

SHANGHAI - China's State FDA launched a new quality system April 10 that requires companies to assign responsibility for drug manufacturing to a drug quality administrator. The move builds accountability into drug manufacturers' systems

Related Content

Latest News
See All
UsernamePublicRestriction

Register

SC073410

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel